After participating in this program, the learner should be able to:
- Describe recent trends in the use of HD catheters and complications associated with their use.
- Verbalize how the design, mechanism, and operation of the access device effects cannulation.
- Provide an overview of clinical outcomes reported to date with the new access system.
- Explain pre and post access care and appropriate nursing interventions.
|
Moderator: Jean M. Nardini, MSN, RN CNN
Director of Patient Care Services
Renal Division
Massachusetts General Hospital
Boston, MA
Christine M. Chmielewski, MS, CRNP, CS, CNN
Nurse Practitioner
Edward J. Filippone, MD, PC & Associates
Philadelphia, PA
Tammy Hlad, RN
Area Clinic Manager
Fresenius Medical Care
Moore, OK
Carl Nettleton
Dialysis patient
Gretna, LA
|
|
 |
This educational
activity is supported by an educational grant from Vasca
Inc. This activity has been planned and produced in accordance with CE
Guidelines and Policies. This educational activity is based on an
official ANNA satellite symposium, but the program was not planned by the
ANNA Program Committee. The series of talks is approved for
1.7 CE Contact Hours by the American Nephrology Nurses' Association (ANNA)
.
|
|
Date of Original Release: August 17, 2002
CE Credit Eligible Through: August 17, 2003
CE Credit Hours/Completion Time: 1.7
Target Audiences: Nephrology Nurses and
Technicians.
Method of participation: Listen to the talk, read the PubMed
abstracts linked to data slides and talk references, take the post-test, read
the linked abstracts in the post-test answer feedback material.
|
Adequate care of end-stage renal disease (ESRD) hemodialysis dependent patient requires constant attention to
the need to maintain vascular access patency. An ideal access delivers a flow
rate adequate for the dialysis prescription, has a long use-life, and has a low rate of complications (eg, infection,
stenosis, thrombosis, aneurysm, and limb ischemia).
Apart from perhaps an AV fistule, no current access type fulfills all of these criteria.
This continuing education activity is based on an approved Satellite Symposium which took place at the American
Nephrology Nurses' Association (ANNA) 2002 Annual Meeting, and is approved by ANNA,
East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing
Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE
to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN
Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738.
This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must
retain this certificate for four years after the CE activity is completed. Other
mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.
The activity provider is HDCN, 15W560 89th St.,
Hinsdale, IL 60527.
The American Nephrology Nurses' Association approves this educational activity for
continuing education credits (Contact Hours) for nurses.
FACULTY DISCLOSURE STATEMENTS
: |
The American Nephrology Nurses' Association, as well as HDCN have conflict of
interest policies that requires course faculty to disclose
any real or apparent commercial financial affiliations related to the
content of their presentations/materials. It is not assumed that these
financial interests or affiliations will have an adverse
impact on faculty presentations; they are simply noted here to fully inform
participants.
Ms. Nardini has nothing to disclose.
Ms. Chmielewski has nothing to disclose.
Ms. Hlad has nothing to disclose.
Mr. Nettleton is on the Patient Advisory Board for Vasca.
DISCLOSURE OF UNLABELED USE: |
This
educational activity may contain discussion of published
and/or
investigational uses of agents that are not indicated by
FDA.
Neither the American Nephrology Nurses' Association nor HDCN
recommend the use of any agent outside of the labeled
indications.
Please refer to the official prescribing information for
each
product for discussion of approved indications,
contraindications
and warnings.
Participants
have an implied responsibility to use the newly acquired
information
to enhance patient outcomes and their own professional
development.
The information presented in this activity is not meant
to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible
contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
|
|